|
G
|
Ache
|
acetylcholinesterase
|
increases activity multiple interactions
|
EXP
|
Galactosamine results in increased activity of ACHE protein Vitamin U inhibits the reaction [Galactosamine results in increased activity of ACHE protein]
|
CTD |
PMID:35673974 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
increases expression multiple interactions
|
EXP
|
Galactosamine results in increased expression of ACTA2 mRNA; Galactosamine results in increased expression of ACTA2 protein Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein]
|
CTD |
PMID:27836788 PMID:27876602 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Actb
|
actin, beta
|
increases expression
|
EXP
|
Galactosamine results in increased expression of ACTB mRNA
|
CTD |
PMID:22563491 |
|
NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242
|
|
G
|
Afp
|
alpha-fetoprotein
|
increases expression
|
EXP
|
Galactosamine results in increased expression of AFP protein
|
CTD |
PMID:61145 PMID:16965562 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:37934488 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Alb
|
albumin
|
multiple interactions increases expression decreases expression
|
EXP
|
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased expression of ALB protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased expression of ALB protein] Galactosamine results in increased expression of ALB mRNA Galactosamine results in decreased expression of ALB protein
|
CTD |
PMID:17963606 PMID:18779383 PMID:22310181 PMID:35838105 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
G
|
Ambp
|
alpha-1-microglobulin/bikunin precursor
|
increases expression
|
EXP
|
Galactosamine results in increased expression of AMBP mRNA
|
CTD |
PMID:18779383 |
|
NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:81,583,622...81,593,850
|
|
G
|
Apoe
|
apolipoprotein E
|
decreases expression
|
EXP
|
Galactosamine results in decreased expression of APOE protein
|
CTD |
PMID:6631239 |
|
NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:88,481,385...88,485,855
|
|
G
|
Atf4
|
activating transcription factor 4
|
multiple interactions
|
EXP
|
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein
|
CTD |
PMID:28844859 |
|
NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739
|
|
G
|
Atm
|
ATM serine/threonine kinase
|
increases expression multiple interactions
|
EXP
|
Galactosamine results in increased expression of ATM protein glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ATM protein]
|
CTD |
PMID:24565947 |
|
NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:62,727,291...62,828,629
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions increases expression
|
ISO EXP
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BAX protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BAX protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BAX protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form] [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX mRNA; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of BAX mRNA] Galactosamine results in increased expression of BAX mRNA; Galactosamine results in increased expression of BAX protein
|
CTD |
PMID:20558151 PMID:20850421 PMID:21401295 PMID:22118634 PMID:24565947 PMID:37934488 More...
|
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions decreases expression
|
ISO EXP
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BCL2 protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BCL2 protein; [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BCL2 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form] Galactosamine results in decreased expression of BCL2 mRNA; Galactosamine results in decreased expression of BCL2 protein glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased expression of BCL2 mRNA]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of BCL2 protein]
|
CTD |
PMID:20558151 PMID:20850421 PMID:22118634 PMID:24565947 PMID:37934488 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bid
|
BH3 interacting domain death agonist
|
multiple interactions
|
EXP
|
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BID mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of BID protein
|
CTD |
PMID:12907702 PMID:21401295 |
|
NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275
|
|
G
|
Casp1
|
caspase 1
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein]
|
CTD |
PMID:32453893 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions increases activity increases expression
|
ISO EXP
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP3 protein]; [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; [Galactosamine co-treated with Endotoxins] results in increased activity of CASP3 protein; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Biliverdine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]; Methylene Chloride inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein] 2-Acetylaminofluorene inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein; Alprostadil inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of CASP3 mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP3 protein] Galactosamine results in increased expression of CASP3 mRNA; Galactosamine results in increased expression of CASP3 protein [Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; Ketoconazole inhibits the reaction [Galactosamine results in increased activity of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein]
|
CTD |
PMID:9388267 PMID:12907702 PMID:14512878 PMID:15486963 PMID:15565661 PMID:15610455 PMID:17602819 PMID:17936189 PMID:20558151 PMID:20850421 PMID:21146893 PMID:21401295 PMID:22023962 PMID:22118634 PMID:22310181 PMID:24565947 PMID:24830863 PMID:26176423 PMID:28887131 PMID:31332890 PMID:32453893 PMID:37934488 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp7
|
caspase 7
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein]
|
CTD |
PMID:21146893 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512
|
|
G
|
Casp8
|
caspase 8
|
multiple interactions
|
ISO
|
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP8 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein]
|
CTD |
PMID:20558151 PMID:20850421 PMID:21146893 PMID:24830863 PMID:31332890 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions increases expression
|
ISO EXP
|
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP9 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein] Galactosamine results in increased expression of CASP9 protein mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP9 protein]
|
CTD |
PMID:20558151 PMID:22118634 PMID:24830863 PMID:31332890 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cat
|
catalase
|
multiple interactions decreases activity increases activity
|
ISO EXP
|
6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Caffeine inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Oligopeptides inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]] [Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of CAT protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of CAT protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased activity of CAT protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of CAT protein]; Vitamin U inhibits the reaction [Galactosamine results in decreased activity of CAT protein]
|
CTD |
PMID:19153979 PMID:22154906 PMID:27836788 PMID:30236599 PMID:31022331 PMID:32453893 PMID:35673974 PMID:35691465 PMID:35838105 More...
|
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
multiple interactions
|
ISO
|
1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of CCL2 mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein; [TNF protein co-treated with Galactosamine] results in increased expression of CCL2 mRNA; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]]
|
CTD |
PMID:21146893 PMID:25200604 PMID:28887131 PMID:35691465 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ccl5
|
C-C motif chemokine ligand 5
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein]
|
CTD |
PMID:21146893 |
|
NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884
|
|
G
|
Cebpa
|
CCAAT/enhancer binding protein alpha
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein; Indomethacin promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein]; nimesulide promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein]
|
CTD |
PMID:22107987 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309
|
|
G
|
Cflar
|
CASP8 and FADD-like apoptosis regulator
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein]
|
CTD |
PMID:20850421 |
|
NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434
|
|
G
|
Chuk
|
component of inhibitor of nuclear factor kappa B kinase complex
|
increases phosphorylation multiple interactions
|
EXP
|
Galactosamine results in increased phosphorylation of CHUK protein mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of CHUK protein]
|
CTD |
PMID:22310181 |
|
NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
increases expression multiple interactions
|
EXP
|
Galactosamine results in increased expression of COL1A1 mRNA Genistein inhibits the reaction [Galactosamine results in increased expression of COL1A1 mRNA]
|
CTD |
PMID:27876602 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Col3a1
|
collagen type III alpha 1 chain
|
multiple interactions increases expression
|
EXP
|
Genistein inhibits the reaction [Galactosamine results in increased expression of COL3A1 mRNA]
|
CTD |
PMID:27876602 |
|
NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232
|
|
G
|
Cpt1a
|
carnitine palmitoyltransferase 1A
|
multiple interactions decreases expression
|
ISO
|
alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CPT1A mRNA]
|
CTD |
PMID:17936189 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326
|
|
G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 protein
|
CTD |
PMID:15576625 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255
|
|
G
|
Cxcl3
|
C-X-C motif chemokine ligand 3
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 protein
|
CTD |
PMID:15576625 |
|
NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624
|
|
G
|
Cyba
|
cytochrome b-245 alpha chain
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein]
|
CTD |
PMID:28887131 |
|
NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214
|
|
G
|
Cycs
|
cytochrome c, somatic
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein]
|
CTD |
PMID:20558151 PMID:20850421 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
decreases expression
|
EXP
|
Galactosamine results in decreased expression of CYP1A2 protein
|
CTD |
PMID:16208626 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
decreases expression multiple interactions
|
EXP
|
Galactosamine results in decreased expression of CYP2E1 protein [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of CYP2E1 protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of CYP2E1 protein]
|
CTD |
PMID:16208626 PMID:35838105 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
decreases expression multiple interactions
|
ISO
|
Galactosamine results in decreased expression of CYP3A4 mRNA alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [alpha-Tocopherol results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]
|
CTD |
PMID:17936189 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
multiple interactions
|
EXP
|
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA
|
CTD |
PMID:28844859 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
multiple interactions
|
EXP
|
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR protein]
|
CTD |
PMID:36414212 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
G
|
Eif2s1
|
eukaryotic translation initiation factor 2 subunit alpha
|
multiple interactions
|
EXP
|
4-phenylbutyric acid affects the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased phosphorylation of EIF2S1 protein]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of and results in decreased phosphorylation of EIF2S1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA
|
CTD |
PMID:28844859 |
|
NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649
|
|
G
|
G6pd
|
glucose-6-phosphate dehydrogenase
|
multiple interactions
|
EXP
|
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of G6PD protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of G6PD protein]
|
CTD |
PMID:35838105 |
|
NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144
|
|
G
|
Gclc
|
glutamate-cysteine ligase, catalytic subunit
|
multiple interactions
|
ISO
|
8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA]
|
CTD |
PMID:35691465 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893
|
|
G
|
Gclm
|
glutamate cysteine ligase, modifier subunit
|
multiple interactions
|
ISO
|
8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GCLM mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA]
|
CTD |
PMID:28887131 PMID:35691465 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003
|
|
G
|
Gdf11
|
growth differentiation factor 11
|
multiple interactions
|
ISO
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GDF11 protein; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BAX protein]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BCL2 protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein]
|
CTD |
PMID:37934488 |
|
NCBI chr 7:1,896,229...1,909,147
Ensembl chr 7:1,896,229...1,905,222
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions increases expression
|
EXP ISO
|
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of GPT protein; Genistein inhibits the reaction [Galactosamine results in increased expression of GPT protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of GPT protein]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of GPT protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of GPT protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of GPT protein] (2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; (2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [idelalisib results in increased expression of ALT protein]; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [Miransertib results in increased expression of ALT protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein; Acetylcysteine inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; stattic inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]
|
CTD |
PMID:19153979 PMID:24565947 PMID:24830863 PMID:25620059 PMID:27876602 PMID:28844859 PMID:28887131 PMID:30236599 PMID:30822415 PMID:31332890 PMID:31445927 PMID:32453893 PMID:35838105 PMID:36414212 PMID:37934488 More...
|
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
multiple interactions decreases activity
|
EXP
|
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of GSR protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of GSR protein]; Vitamin U inhibits the reaction [Galactosamine results in decreased activity of GSR protein]
|
CTD |
PMID:35673974 PMID:35838105 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
G
|
Gstt3
|
glutathione S-transferase, theta 3
|
affects response to substance
|
EXP
|
GSTT3 mRNA affects the susceptibility to Galactosamine
|
CTD |
PMID:19800905 |
|
NCBI chr20:12,873,618...12,881,974
Ensembl chr20:12,874,374...12,881,973
|
|
G
|
H3f4
|
H3.4 histone, cluster member
|
increases expression
|
EXP
|
Galactosamine results in increased expression of H3F4 mRNA
|
CTD |
PMID:11779202 |
|
NCBI chr10:44,240,282...44,240,842
|
|
G
|
Habp2
|
hyaluronan binding protein 2
|
increases activity
|
ISO
|
Galactosamine results in increased activity of HABP2 protein
|
CTD |
PMID:11510480 |
|
NCBI chr 1:265,321,084...265,355,375
Ensembl chr 1:265,303,172...265,355,374
|
|
G
|
Hbegf
|
heparin-binding EGF-like growth factor
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA]
|
CTD |
PMID:28887131 |
|
NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220
|
|
G
|
Hgf
|
hepatocyte growth factor
|
multiple interactions
|
EXP
|
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein
|
CTD |
PMID:28844859 |
|
NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions decreases expression
|
ISO EXP
|
8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein; Galactosamine inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]] [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA] which results in increased chemical synthesis of Bilirubin; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of HMOX1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA; mangiferin inhibits the reaction [Galactosamine results in decreased expression of HMOX1 protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of HMOX1 protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]
|
CTD |
PMID:14512878 PMID:19796704 PMID:21401295 PMID:22310181 PMID:35691465 PMID:35838105 More...
|
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hp
|
haptoglobin
|
multiple interactions
|
EXP
|
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HP protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HP protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HP protein]
|
CTD |
PMID:36414212 |
|
NCBI chr19:54,449,151...54,453,701
Ensembl chr19:54,446,217...54,467,518
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
multiple interactions
|
EXP
|
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein
|
CTD |
PMID:28844859 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
multiple interactions
|
ISO
|
Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein] 1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of ICAM1 mRNA]; [TNF protein co-treated with Galactosamine] results in increased expression of ICAM1 mRNA
|
CTD |
PMID:16431966 PMID:25200604 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions increases expression
|
ISO EXP
|
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein] Galactosamine results in increased expression of IFNG mRNA mangiferin inhibits the reaction [Galactosamine results in increased expression of IFNG mRNA]
|
CTD |
PMID:15486963 PMID:22310181 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Igfbp1
|
insulin-like growth factor binding protein 1
|
increases expression
|
EXP
|
Galactosamine results in increased expression of IGFBP1 mRNA
|
CTD |
PMID:11779202 |
|
NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344
|
|
G
|
Ikbkb
|
inhibitor of nuclear factor kappa B kinase subunit beta
|
multiple interactions increases phosphorylation
|
EXP
|
mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of IKBKB protein]
|
CTD |
PMID:22310181 |
|
NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions decreases expression
|
ISO EXP
|
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein] [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; mangiferin inhibits the reaction [Galactosamine results in decreased expression of IL10 mRNA]
|
CTD |
PMID:15486963 PMID:17963606 PMID:22310181 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il12b
|
interleukin 12B
|
multiple interactions increases expression
|
ISO EXP
|
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA Galactosamine results in increased expression of IL12B mRNA mangiferin inhibits the reaction [Galactosamine results in increased expression of IL12B mRNA]
|
CTD |
PMID:19913045 PMID:22310181 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
|
|
G
|
Il18
|
interleukin 18
|
increases expression multiple interactions
|
ISO EXP
|
Galactosamine results in increased expression of IL18 mRNA; Galactosamine results in increased expression of IL18 protein [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 protein] mangiferin inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]
|
CTD |
PMID:19913045 PMID:20102673 PMID:22310181 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases expression
|
EXP ISO
|
Genistein inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA] 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; nilotinib inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL1B protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]]
|
CTD |
PMID:15135310 PMID:22310181 PMID:25620059 PMID:28125915 PMID:28887131 PMID:30550845 PMID:32453893 PMID:35691465 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions increases expression
|
ISO EXP
|
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]] [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of IL6 protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of IL6 protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of IL6 protein]
|
CTD |
PMID:15135310 PMID:15486963 PMID:22310181 PMID:24830863 PMID:27836788 PMID:28887131 PMID:31332890 PMID:32453893 PMID:35691465 PMID:36414212 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Irak1
|
interleukin-1 receptor-associated kinase 1
|
multiple interactions
|
ISO
|
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of IRAK1 protein; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]]
|
CTD |
PMID:28213090 |
|
NCBI chr X:156,919,927...156,929,825
Ensembl chr X:156,920,081...156,929,825
|
|
G
|
Keap1
|
Kelch-like ECH-associated protein 1
|
multiple interactions
|
ISO
|
8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein]
|
CTD |
PMID:35691465 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042
|
|
G
|
Lcat
|
lecithin cholesterol acyltransferase
|
decreases activity
|
EXP
|
Galactosamine results in decreased activity of LCAT protein
|
CTD |
PMID:6631239 |
|
NCBI chr19:50,744,598...50,748,064
Ensembl chr19:50,744,601...50,748,081
|
|
G
|
Lep
|
leptin
|
multiple interactions increases response to substance
|
ISO
|
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine]
|
CTD |
PMID:19913045 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661
|
|
G
|
Lepr
|
leptin receptor
|
multiple interactions increases response to substance
|
ISO
|
[LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine]
|
CTD |
PMID:19913045 |
|
NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions increases phosphorylation
|
ISO EXP
|
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK1 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form] Galactosamine results in increased phosphorylation of MAPK1 protein Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions increases phosphorylation
|
ISO EXP
|
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form] Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Maz
|
MYC associated zinc finger protein
|
multiple interactions
|
EXP
|
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ protein]
|
CTD |
PMID:36414212 |
|
NCBI chr 1:181,629,742...181,635,193
Ensembl chr 1:191,060,280...191,065,339
|
|
G
|
Met
|
MET proto-oncogene, receptor tyrosine kinase
|
multiple interactions
|
EXP ISO
|
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MET mRNA
|
CTD |
PMID:28844859 PMID:28887131 |
|
NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821
|
|
G
|
Mgst1
|
microsomal glutathione S-transferase 1
|
multiple interactions
|
EXP
|
[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of MGST1 protein; Dithiothreitol inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of MGST1 protein]
|
CTD |
PMID:18634816 |
|
NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:172,760,886...172,776,875
|
|
G
|
Mir34c
|
microRNA 34c
|
multiple interactions
|
EXP
|
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MIR34C mRNA; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MIR34C mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MIR34C mRNA]
|
CTD |
PMID:36414212 |
|
NCBI chr 8:60,306,091...60,306,167
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions increases activity
|
ISO EXP
|
(2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein] [Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of MPO protein]; Vitamin U inhibits the reaction [Galactosamine results in increased activity of MPO protein]
|
CTD |
PMID:28887131 PMID:30550845 PMID:31022331 PMID:32453893 PMID:35673974 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
multiple interactions
|
ISO
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein]
|
CTD |
PMID:37934488 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Ndufb6
|
NADH:ubiquinone oxidoreductase subunit B6
|
multiple interactions decreases expression
|
ISO
|
Acetylcysteine inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; coenzyme Q10 inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]
|
CTD |
PMID:19523936 |
|
NCBI chr 5:60,196,585...60,206,152
Ensembl chr 5:60,196,585...60,206,055
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
affects localization decreases expression multiple interactions increases activity
|
EXP ISO
|
Galactosamine affects the localization of NFE2L2 protein Galactosamine results in decreased expression of NFE2L2 protein mangiferin affects the reaction [Galactosamine affects the localization of NFE2L2 protein]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFE2L2 protein] [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein] Galactosamine results in increased activity of NFE2L2 protein
|
CTD |
PMID:22310181 PMID:28887131 PMID:30114225 PMID:30203046 PMID:30236599 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]
|
CTD |
PMID:17936189 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions decreases expression
|
EXP ISO
|
Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein] [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein]
|
CTD |
PMID:15565661 PMID:20850421 PMID:22310181 PMID:28213090 PMID:30550845 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein]
|
CTD |
PMID:32453893 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions increases expression
|
ISO EXP
|
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein] [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitrites; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 promoter]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]]; Galactosamine promotes the reaction [Alprostadil results in increased expression of NOS2 protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA] Galactosamine results in increased expression of NOS2 mRNA; Galactosamine results in increased expression of NOS2 promoter; Galactosamine results in increased expression of NOS2 protein alpha-Tocopherol inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]
|
CTD |
PMID:15189274 PMID:15565661 PMID:17936189 PMID:19796704 PMID:21401295 PMID:22107987 PMID:22118634 PMID:22310181 PMID:25620059 More...
|
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
decreases expression multiple interactions
|
EXP ISO
|
Galactosamine results in decreased expression of NQO1 protein mangiferin inhibits the reaction [Galactosamine results in decreased expression of NQO1 protein] 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NQO1 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein]
|
CTD |
PMID:22310181 PMID:28887131 PMID:35691465 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Ocln
|
occludin
|
multiple interactions
|
EXP
|
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN protein]
|
CTD |
PMID:36414212 |
|
NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions
|
ISO
|
[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein]
|
CTD |
PMID:20558151 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pik3r1
|
phosphoinositide-3-kinase regulatory subunit 1
|
multiple interactions
|
ISO
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein]
|
CTD |
PMID:37934488 |
|
NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
increases expression decreases expression multiple interactions increases activity
|
ISO
|
Galactosamine results in increased expression of PPARA mRNA Galactosamine results in decreased expression of PPARA mRNA alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of PPARA mRNA] Galactosamine results in increased activity of PPARA protein [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein
|
CTD |
PMID:17936189 PMID:25689681 PMID:30203046 PMID:30236599 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions
|
ISO
|
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein]
|
CTD |
PMID:30236599 PMID:30550845 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Ppia
|
peptidylprolyl isomerase A
|
decreases expression
|
EXP
|
Galactosamine results in decreased expression of CYCA mRNA
|
CTD |
PMID:22563491 |
|
NCBI chr14:85,491,223...85,496,884
Ensembl chr14:85,492,484...85,497,115
|
|
G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA]
|
CTD |
PMID:22107987 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions increases expression
|
ISO EXP
|
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein] Galactosamine results in increased expression of PTGS2 protein Genistein inhibits the reaction [Galactosamine results in increased expression of PTGS2 protein]
|
CTD |
PMID:22107987 PMID:25620059 PMID:32453893 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Ptn
|
pleiotrophin
|
increases expression
|
EXP
|
Galactosamine results in increased expression of PTN mRNA; Galactosamine results in increased expression of PTN protein
|
CTD |
PMID:12057922 |
|
NCBI chr 4:66,260,764...66,342,614
Ensembl chr 4:66,260,764...66,342,482
|
|
G
|
Pttg1
|
PTTG1 regulator of sister chromatid separation, securin
|
affects response to substance
|
EXP
|
PTTG1 mRNA affects the susceptibility to Galactosamine
|
CTD |
PMID:19800905 |
|
NCBI chr10:28,394,940...28,406,410
Ensembl chr10:28,394,814...28,406,309
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions increases expression
|
ISO EXP
|
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein] Galactosamine results in increased expression of RELA protein mangiferin inhibits the reaction [Galactosamine results in increased expression of RELA protein] alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]
|
CTD |
PMID:17936189 PMID:20850421 PMID:22310181 PMID:30550845 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Sdc3
|
syndecan 3
|
increases expression
|
EXP
|
Galactosamine results in increased expression of SDC3 mRNA
|
CTD |
PMID:12057922 |
|
NCBI chr 5:142,965,659...142,998,390
Ensembl chr 5:148,271,842...148,280,614
|
|
G
|
Serpine1
|
serpin family E member 1
|
increases expression
|
EXP
|
Galactosamine results in increased expression of SERPINE1 mRNA
|
CTD |
PMID:11779202 |
|
NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357
|
|
G
|
Sesn2
|
sestrin 2
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 protein
|
CTD |
PMID:25637945 |
|
NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255
|
|
G
|
Smad2
|
SMAD family member 2
|
multiple interactions increases phosphorylation
|
EXP
|
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD2 protein]
|
CTD |
PMID:27876602 |
|
NCBI chr18:72,124,792...72,193,345
Ensembl chr18:72,124,863...72,187,388
|
|
G
|
Smad3
|
SMAD family member 3
|
multiple interactions increases phosphorylation
|
EXP
|
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD3 protein]
|
CTD |
PMID:27876602 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324
|
|
G
|
Smad7
|
SMAD family member 7
|
multiple interactions decreases expression
|
EXP
|
Genistein inhibits the reaction [Galactosamine results in decreased expression of SMAD7 protein]
|
CTD |
PMID:27876602 |
|
NCBI chr18:71,263,508...71,291,849
Ensembl chr18:71,263,508...71,291,849
|
|
G
|
Sod1
|
superoxide dismutase 1
|
multiple interactions
|
EXP
|
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of SOD1 mRNA
|
CTD |
PMID:21401295 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sord
|
sorbitol dehydrogenase
|
multiple interactions
|
ISO
|
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein]
|
CTD |
PMID:30822415 |
|
NCBI chr 3:129,638,282...129,669,727
Ensembl chr 3:129,638,302...129,686,100
|
|
G
|
Spp1
|
secreted phosphoprotein 1
|
multiple interactions
|
ISO
|
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine]
|
CTD |
PMID:19913045 |
|
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein]
|
CTD |
PMID:28887131 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
G
|
Stat5b
|
signal transducer and activator of transcription 5B
|
decreases activity
|
ISO
|
Galactosamine results in decreased activity of STAT5B protein
|
CTD |
PMID:30114225 |
|
NCBI chr10:86,205,148...86,276,178
Ensembl chr10:86,207,293...86,275,990
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
increases expression multiple interactions
|
EXP
|
Galactosamine results in increased expression of TGFB1 mRNA; Galactosamine results in increased expression of TGFB1 protein Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein]
|
CTD |
PMID:27836788 PMID:27876602 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tjp1
|
tight junction protein 1
|
multiple interactions
|
EXP
|
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 protein]
|
CTD |
PMID:36414212 |
|
NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158
|
|
G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein]
|
CTD |
PMID:28125915 PMID:32453893 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions increases expression
|
ISO EXP
|
1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of CCL2 mRNA]; 1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of ICAM1 mRNA]; 1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of VCAM1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; [TNF protein co-treated with Galactosamine] results in increased expression of CCL2 mRNA; [TNF protein co-treated with Galactosamine] results in increased expression of ICAM1 mRNA; [TNF protein co-treated with Galactosamine] results in increased expression of VCAM1 mRNA; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; hydroquinone metabolite inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; nilotinib inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Prednisolone inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]] [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; Alprostadil promotes the reaction [Galactosamine results in increased expression of TNF protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of TNF protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF protein] [Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein] Galactosamine results in increased expression of TNF mRNA; Galactosamine results in increased expression of TNF protein
|
CTD |
PMID:9388267 PMID:10221824 PMID:11779202 PMID:14512878 PMID:15135310 PMID:15486963 PMID:16431966 PMID:17602819 PMID:17963606 PMID:20054000 PMID:20558151 PMID:22107987 PMID:22118634 PMID:22310181 PMID:24565947 PMID:24830863 PMID:25200604 PMID:25620059 PMID:26176423 PMID:27836788 PMID:28125915 PMID:28213090 PMID:28887131 PMID:30550845 PMID:30822415 PMID:31332890 PMID:32453893 PMID:35691465 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Traf6
|
TNF receptor associated factor 6
|
multiple interactions
|
ISO
|
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]]
|
CTD |
PMID:28213090 |
|
NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328
|
|
G
|
Vcam1
|
vascular cell adhesion molecule 1
|
multiple interactions
|
ISO
|
1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of VCAM1 mRNA]; [TNF protein co-treated with Galactosamine] results in increased expression of VCAM1 mRNA
|
CTD |
PMID:25200604 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
multiple interactions
|
EXP
|
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA
|
CTD |
PMID:28844859 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
G
|
Xdh
|
xanthine dehydrogenase
|
increases activity multiple interactions
|
EXP
|
Galactosamine results in increased activity of XDH protein Vitamin U inhibits the reaction [Galactosamine results in increased activity of XDH protein]
|
CTD |
PMID:35673974 |
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350
|
|
G
|
Xiap
|
X-linked inhibitor of apoptosis
|
multiple interactions
|
ISO
|
[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein]
|
CTD |
PMID:20850421 |
|
NCBI chr X:125,756,107...125,803,979
Ensembl chr X:125,737,971...125,803,978
|
|